CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

GlaxoSmithKline (GSK)

The GlaxoSmithKline CRUSH Report is a Global 500 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The GlaxoSmithKline CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The GlaxoSmithKline CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The GlaxoSmithKline CRUSH Report has the competitive intelligence needed for account planning within the Global 500. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

GSK news

GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news.

Two overall winners announced at prestigious national award ceremony in London’s Science Museum
Friday May 18th 2012 07:13:18 AM

For the first time in its 15 year history the judges of the GlaxoSmithKline (GSK) IMPACT Awards could not choose one overall winner for the awards so instead awarded two prizes.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GSK statement on tender offer to acquire Human Genome Sciences
Thursday May 17th 2012 12:50:05 PM

GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors’ decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash. The offer represents a premium of 81 percent to HGS’s closing share price of US$7.17 on 18th April, the last trading day before HGS publicly disclosed GSK’s private offer. The offer is not conditioned on due diligence or financing.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GlaxoSmithKline completes transaction to increase its ownership in Theravance
Wednesday May 16th 2012 09:21:50 AM

GlaxoSmithKline plc (“GSK”) (LSE:GSK) and Theravance, Inc. (“Theravance”) (NASDAQ: THRX) announced today that following approval by Theravance, Inc.‟s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK‟s acquisition of 10,000,000 shares of Theravance common stock on the terms previously announced on 2 April 2012, has now completed.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GlaxoSmithKline to fully acquire Cellzome for £61 million
Tuesday May 15th 2012 05:03:54 AM

GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash. Cellzome, a privately owned company with laboratories in Cambridge, UK, and Heidelberg, Germany, will become part of GSK’s R&D organisation.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GSK statement on BBC Panorama broadcast: ‘the truth about tax’
Monday May 14th 2012 04:10:00 PM

GSK statement on BBC Panorama broadcast: ‘the truth about tax’

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
Friday May 11th 2012 07:08:25 PM

Stiefel, a GSK (NYSE:GSK) company, today announced that the US Food and Drug Administration has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
Thursday May 10th 2012 07:55:27 AM

GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
Wednesday May 9th 2012 02:36:50 AM

GSK announced that it will not participate in Human Genome Sciences strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.  

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

James Shannon named GlaxoSmithKline Chief Medical Officer
Friday May 4th 2012 05:28:09 AM

James Shannon has been named GSK's Chief Medical Officer (CMO), effective 1 May. James will report to R&D Chairman Moncef Slaoui and be based in London. He will be accountable for medical governance and patient safety for all of GSK: Pharmaceuticals, Consumer Healthcare, Vaccines and the global businesses.

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
Thursday May 3rd 2012 08:39:24 AM

GlaxoSmithKline plc appoints two Non-Executive Directors to its Board

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati